title: N-Acetyl-Aspartate Level is Decreased in the Prefrontal Cortex in Subjects At-Risk for Schizophrenia.
abstract: Reduced N-acetyl-aspartate (NAA) levels have been reported in the prefrontal cortex (PFC) in patients with schizophrenia using proton magnetic resonance spectroscopy. However, it is unclear whether this NAA reduction predates the illness onset and is reported in subjects at-risk for developing schizophrenia (HRS). The aim of this study was to assess NAA levels in the PFC in HRS. We hypothesized that HRS display lower NAA levels than healthy controls in the PFC. Studies assessing levels of NAA/Creatine (NAA/Cr) in the PFC in HRS were extracted from literature. Meta-analysis tools were used to compute effect sizes of nine selected studies meeting our inclusion criteria (clinical and/or genetic HRS, groups of HRS, and healthy controls matched for age and gender, spectral acquisition in the PFC). We reported that HRS exhibited a significant lower NAA/Cr level (2.15 ± 0.29; n = 208) than healthy controls (2.21 ± 0.32; n = 234) in the PFC with a medium pooled effect size [Hedges's g = -0.42; 95% confidence interval: (-0.61; -0.23); p < 0.0001] corresponding to an average 5.7% of NAA/Cr decrease. Secondary analysis revealed that this reduction was observed in young HRS (<40 years old) who have not reached the peak age of risk for schizophrenia (-11%, g = -0.82, p < 0.00001) but not in old HRS (>40 years old) who have already passed the peak age (g = 0.11, p = 0.56), when they are compared with their matched healthy controls. Our findings suggest that the NAA/Cr reduction in the PFC reported in patients with schizophrenia is observable only in HRS who have not passed the peak age of risk for schizophrenia. NAA/Cr level in the PFC could therefore be considered as a biological vulnerability marker of schizophrenia.
authors.affiliation: EA4615, CH le Vinatier, Université Claude Bernard Lyon 1 , Lyon , France.
authors.forename: Marine
authors.initials: M
authors.lastname: Mondino
authors.forename: Jerome
authors.initials: J
authors.lastname: Brunelin
authors.forename: Mohamed
authors.initials: M
authors.lastname: Saoud
keywords: MRS; NAA; prefrontal cortex; risk; schizophrenia; vulnerability
references.citation: Schizophr Res. 2005 Mar 1;73(2-3):209-19
references.pmid: 15653263
references.citation: Schizophr Res. 2007 Jan;89(1-3):287-92
references.pmid: 17029909
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1997 Nov;21(8):1285-95
references.pmid: 9460092
references.citation: Acta Psychiatr Scand. 1994 Feb;89(2):135-41
references.pmid: 8178665
references.citation: Schizophr Bull. 2002;28(2):329-39
references.pmid: 12693438
references.citation: Mol Psychiatry. 2010 Mar;15(3):308-18
references.pmid: 18645571
references.citation: J Neurosci. 1993 Mar;13(3):981-9
references.pmid: 8441018
references.citation: Psychiatry Res. 2007 Oct 15;156(1):33-42
references.pmid: 17764911
references.citation: Biol Psychiatry. 1998 Nov 15;44(10):941-50
references.pmid: 9821558
references.citation: Am J Psychiatry. 2003 Dec;160(12):2231-3
references.pmid: 14638596
references.citation: Biol Psychiatry. 2011 Mar 1;69(5):495-503
references.pmid: 21145039
references.citation: Am J Psychiatry. 2004 Jun;161(6):1116-8
references.pmid: 15169703
references.citation: Neuropsychopharmacology. 2005 Nov;30(11):1949-62
references.pmid: 16123764
references.citation: Curr Med Chem. 2013;20(3):414-27
references.pmid: 23157634
references.citation: Int Rev Psychiatry. 2007 Aug;19(4):371-81
references.pmid: 17671870
references.citation: Rev Neurosci. 2000;11(2-3):147-58
references.pmid: 10718151
references.citation: Schizophr Res. 2008 Feb;99(1-3):218-24
references.pmid: 18248960
references.citation: Biol Psychiatry. 2008 Jan 1;63(1):65-71
references.pmid: 17574215
references.citation: Schizophr Res. 2009 Mar;108(1-3):85-92
references.pmid: 19138834
references.citation: Arch Gen Psychiatry. 1987 Jul;44(7):660-9
references.pmid: 3606332
references.citation: Schizophr Res. 2006 Oct;87(1-3):81-8
references.pmid: 16842971
references.citation: Schizophr Bull. 2000;26(4):893-902
references.pmid: 11087021
references.citation: Psychiatry Res. 2006 Nov 22;148(1):23-31
references.pmid: 17052898
references.citation: Schizophr Res. 2009 Jun;111(1-3):86-93
references.pmid: 19406622
references.citation: Biol Psychiatry. 1998 Feb 15;43(4):263-9
references.pmid: 9513735
references.citation: Am J Psychiatry. 2005 Dec;162(12):2322-9
references.pmid: 16330597
references.citation: Acta Psychiatr Scand Suppl. 1994;384:71-9
references.pmid: 7879647
references.citation: AJNR Am J Neuroradiol. 2001 Jan;22(1):119-27
references.pmid: 11158897
references.citation: Biol Psychiatry. 2001 Jan 1;49(1):39-46
references.pmid: 11163778
references.citation: J Neuroradiol. 2009 Mar;36(1):24-40
references.pmid: 18539330
references.citation: JAMA Psychiatry. 2013 Jan;70(1):107-20
references.pmid: 23165428
references.citation: Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):117-28
references.pmid: 15146341
references.citation: Schizophr Res. 2005 Mar 1;73(2-3):153-7
references.pmid: 15653258
references.citation: Schizophr Bull. 2003;29(4):831-43
references.pmid: 14989417
references.citation: Neuropsychol Rev. 2009 Sep;19(3):385-98
references.pmid: 19728098
references.citation: Schizophr Bull. 2012 Nov;38(6):1268-76
references.pmid: 22290265
references.citation: Arch Gen Psychiatry. 2006 Sep;63(9):969-76
references.pmid: 16952999
references.citation: Neurosci Lett. 2000 Aug 4;289(2):147-51
references.pmid: 10904141
references.citation: Korean J Radiol. 2006 Jul-Sep;7(3):156-61
references.pmid: 16969044